Lesotho
Tuberculosis profile
| High HIV burden |
Population  2012 2.1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.34 (<0.01–1.4) 17 (0.18–68)
Mortality (HIV+TB only) 1.5 (1.3–1.9) 75 (63–92)
Prevalence  (includes HIV+TB) 8.7 (2.7–18) 424 (130–888)
Incidence  (includes HIV+TB) 13 (11–15) 630 (550–716)
Incidence (HIV+TB only) 9.9 (8.7–11) 485 (423–550)
Case detection, all forms (%) 83 (73–95)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 3 298 (32) Relapse 459 (28)
Smear-negative 3 385 (33) Treatment after failure 45 (3)
Smear-unknown / not done 1 757 (17) Treatment after default 61 (4)
Extrapulmonary 1 877 (18) Other 1 089 (66)
Other          
Total new 10 317   Total retreatment 1 654  
           
Other (history unknown)          
Total new and relapse 10 776   Total cases notified 11 971  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.2 1.1 1.1
Age < 15 45 466 72
Laboratories 2012
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 2.4
Drug susceptibility testing (per 5 million population) 2.4
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 74   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 66  
Retreatment 58  
TB/HIV 2012 Number (%)
TB patients with known HIV status 10 476 (88)
HIV-positive TB patients 7 878 (75)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 7 637 (97)
HIV-positive TB patients on antiretroviral therapy (ART) 4 171 (53)
HIV-positive people screened for TB 21 408  
HIV-positive people provided with IPT 16 403  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.91 (0.19–2.6) 5.7 (1.2–16)
MDR-TB cases among notified pulmonary
TB cases
77 (16–220) 94 (20–260)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 5 (<1%) 28 (2%) 55
Laboratory-confirmed MDR-TB cases 3 28 46
Patients started on MDR-TB treatment     189
Financing TB control 2013
National TB programme budget (US$ millions) 4
% Funded domestically 34%
% Funded internationally 55%
% Unfunded 10%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-21 Data: www.who.int/tb/data